vs
MACROGENICS INC（MGNX）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是MACROGENICS INC的1.2倍（$50.3M vs $41.2M），MACROGENICS INC同比增速更快（113.0% vs -14.2%），MACROGENICS INC自由现金流更多（$42.8M vs $4.1M），过去两年MACROGENICS INC的营收复合增速更高（112.8% vs 5.6%）
MacroGenics Inc是一家临床阶段生物制药公司，专注于研发针对癌症和自身免疫性疾病的新型免疫疗法，核心产品管线以单克隆抗体类治疗药物为核心，重点项目覆盖实体瘤与血液恶性肿瘤，通过与全球药企合作推进产品落地。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
MGNX vs RDI — 直观对比
营收规模更大
RDI
是对方的1.2倍
$41.2M
营收增速更快
MGNX
高出127.2%
-14.2%
自由现金流更多
MGNX
多$38.7M
$4.1M
两年增速更快
MGNX
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $50.3M |
| 净利润 | — | $-2.6M |
| 毛利率 | — | — |
| 营业利润率 | -29.3% | -1.9% |
| 净利率 | — | -5.1% |
| 营收同比 | 113.0% | -14.2% |
| 净利润同比 | — | -14.5% |
| 每股收益（稀释后） | $-0.23 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MGNXRDI
| Q4 25 | $41.2M | $50.3M | ||
| Q3 25 | $72.8M | $52.2M | ||
| Q2 25 | $22.2M | $60.4M | ||
| Q1 25 | $13.2M | $40.2M | ||
| Q4 24 | $19.4M | $58.6M | ||
| Q3 24 | $110.7M | $60.1M | ||
| Q2 24 | $10.8M | $46.8M | ||
| Q1 24 | $9.1M | $45.1M |
净利润MGNXRDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $16.8M | $-4.2M | ||
| Q2 25 | $-36.3M | $-2.7M | ||
| Q1 25 | $-41.0M | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $56.3M | $-7.0M | ||
| Q2 24 | $-55.7M | $-12.8M | ||
| Q1 24 | $-52.2M | $-13.2M |
毛利率MGNXRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 98.8% | — | ||
| Q3 24 | 99.8% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 97.0% | — |
营业利润率MGNXRDI
| Q4 25 | -29.3% | -1.9% | ||
| Q3 25 | 25.6% | -0.6% | ||
| Q2 25 | -165.3% | 4.8% | ||
| Q1 25 | -323.1% | -17.2% | ||
| Q4 24 | -273.0% | 2.6% | ||
| Q3 24 | 48.9% | -0.6% | ||
| Q2 24 | -538.9% | -16.4% | ||
| Q1 24 | -590.4% | -16.7% |
净利率MGNXRDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | 23.1% | -8.0% | ||
| Q2 25 | -163.0% | -4.4% | ||
| Q1 25 | -311.1% | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | 50.9% | -11.7% | ||
| Q2 24 | -515.6% | -27.4% | ||
| Q1 24 | -573.3% | -29.4% |
每股收益（稀释后）MGNXRDI
| Q4 25 | $-0.23 | $-0.11 | ||
| Q3 25 | $0.27 | $-0.18 | ||
| Q2 25 | $-0.57 | $-0.12 | ||
| Q1 25 | $-0.65 | $-0.21 | ||
| Q4 24 | $-0.24 | $-0.11 | ||
| Q3 24 | $0.90 | $-0.31 | ||
| Q2 24 | $-0.89 | $-0.57 | ||
| Q1 24 | $-0.84 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.2M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $55.6M | $-18.2M |
| 总资产 | $256.8M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MGNXRDI
| Q4 25 | $57.2M | $10.5M | ||
| Q3 25 | $80.1M | $8.1M | ||
| Q2 25 | $130.7M | $9.1M | ||
| Q1 25 | $145.6M | $5.9M | ||
| Q4 24 | $182.8M | $12.4M | ||
| Q3 24 | $179.6M | $10.1M | ||
| Q2 24 | $83.9M | $9.3M | ||
| Q1 24 | $80.4M | $7.5M |
总债务MGNXRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MGNXRDI
| Q4 25 | $55.6M | $-18.2M | ||
| Q3 25 | $67.0M | $-12.1M | ||
| Q2 25 | $46.6M | $-7.7M | ||
| Q1 25 | $79.1M | $-8.1M | ||
| Q4 24 | $116.1M | $-4.4M | ||
| Q3 24 | $120.1M | $1.6M | ||
| Q2 24 | $57.8M | $6.5M | ||
| Q1 24 | $106.2M | $18.0M |
总资产MGNXRDI
| Q4 25 | $256.8M | $434.9M | ||
| Q3 25 | $270.8M | $435.2M | ||
| Q2 25 | $245.4M | $438.1M | ||
| Q1 25 | $224.6M | $441.0M | ||
| Q4 24 | $261.7M | $471.0M | ||
| Q3 24 | $264.5M | $495.7M | ||
| Q2 24 | $201.1M | $494.9M | ||
| Q1 24 | $248.3M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.0M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $42.8M | $4.1M |
| 自由现金流率自由现金流/营收 | 103.8% | 8.2% |
| 资本支出强度资本支出/营收 | 0.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-83.0M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流MGNXRDI
| Q4 25 | $43.0M | $4.3M | ||
| Q3 25 | $-30.2M | $295.0K | ||
| Q2 25 | $-47.0M | $1.6M | ||
| Q1 25 | $-46.9M | $-7.7M | ||
| Q4 24 | $-38.4M | $8.0M | ||
| Q3 24 | $60.2M | $1.3M | ||
| Q2 24 | $-44.5M | $-10.4M | ||
| Q1 24 | $-45.6M | $-2.8M |
自由现金流MGNXRDI
| Q4 25 | $42.8M | $4.1M | ||
| Q3 25 | $-30.6M | $-246.0K | ||
| Q2 25 | $-47.7M | $1.2M | ||
| Q1 25 | $-47.4M | $-8.0M | ||
| Q4 24 | $-39.0M | $7.0M | ||
| Q3 24 | $59.6M | $-1.1M | ||
| Q2 24 | $-45.5M | $-10.6M | ||
| Q1 24 | $-47.1M | $-4.7M |
自由现金流率MGNXRDI
| Q4 25 | 103.8% | 8.2% | ||
| Q3 25 | -42.0% | -0.5% | ||
| Q2 25 | -214.5% | 1.9% | ||
| Q1 25 | -359.5% | -19.8% | ||
| Q4 24 | -201.7% | 12.0% | ||
| Q3 24 | 53.8% | -1.8% | ||
| Q2 24 | -421.6% | -22.7% | ||
| Q1 24 | -517.4% | -10.4% |
资本支出强度MGNXRDI
| Q4 25 | 0.6% | 0.3% | ||
| Q3 25 | 0.6% | 1.0% | ||
| Q2 25 | 3.2% | 0.6% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 3.2% | 1.7% | ||
| Q3 24 | 0.5% | 4.0% | ||
| Q2 24 | 9.6% | 0.5% | ||
| Q1 24 | 16.0% | 4.3% |
现金转化率MGNXRDI
| Q4 25 | — | — | ||
| Q3 25 | -1.79× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.07× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGNX
| Revenue From Collaborative Agreements | $20.3M | 49% |
| Contract Manufacturing | $11.3M | 27% |
| Other | $9.7M | 23% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
